User-friendly report form guides healthcare providers to clear-cut, data-driven treatment decisions. The report form was developed by experienced clinical experts and then fine-tuned based on healthcare providers' feedback. PhenoSenseGT report provides actual phenotype and genotype resistance data side by side, along with replication capacity (RC) and HIV subtype, to allow easy comparison and straightforward use.
Net Assessment: Sensitive, Partially Sensitive, Resistant
The PhenoSenseGT report makes it easy to interpret resistance data.
- Resolves disagreement between phenotype and genotype results
- "Partially Sensitive" assessment highlights a middle zone of susceptibility, to identify potential treatment options when choices are limited – especially useful in choosing nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs)
PhenoSense Clinical Cutoffs Complete the Susceptibility Picture
Clinical cutoff values reflect the incremental impact of a single drug. PhenoSenseGT graphically plots the fold change of the patient's virus against the lower and upper cutoffs for each drug.
- Blue bar indicates susceptibility, or hypersusceptibility if the bar extends to the left
- Striped bar indicates partial sensitivity – the "zone of intermediate response" in which susceptibility falls between upper and lower cutoffs
- Black bars indicate drug resistance with higher levels farther to the right
How to Interpret Cutoffs
Tenofovir has a lower cutoff of 1.4 and an upper cutoff of 4. If a patient's HIV phenotype fold change falls above 4, there is unlikely to be any response to the drug. If a PhenoSense result falls between 1.4 and 4, it predicts partial response to tenofovir1.
Genotype Mutations
PhenoSenseGT clearly lists the individual mutations for each class of drug.
- Detects minority, emerging, and regressing populations of drug-resistant virus
- Mixtures of mutated virus populations are indicated by a slash as in L74I/V
Assessment Summary
The first page of the PhenoSenseGT report provides an easy-to-use snapshot of the net assessment result for each drug.
- Quick overview of potential treatment options within each drug class for each patient
Replication Capacity (RC)
PhenoSense technology measures the effects of resistance mutations on the ability of the virus to replicate in comparison to a non-resistant "wild-type" virus. Resistance is measured in the reverse transcriptase and protease genes, which are the targets of most antiretroviral drugs. A replication capacity of 100% is the median of wild-type virus.
- Lower replication capacity suggests a less fit virus, which may be associated with slower disease progression
Patient Tracking
Providers can record a patient’s treatment history, viral load, and CD4 counts on the PhenoSenseGT report.
HIV Subtype
Non-B subtypes are becoming more common, and develop resistance through different mutational patterns than the subtype B virus.
- Knowing subtype could help to select the most effective treatment regimen
|
Download Sample PhenoSense GT Report |